SCHEMBL13081202

SCHEMBL13081202

O=C1Nc2ccc(F)cc2/C1=C/c1ccc[nH]1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 5/20 0.80
▸ TLK2 Q86UE8 4/20 0.74
▸ PDPK1 O15530 8/20 0.71
▸ RET P07949 4/20 0.71
▸ KDR P35968 4/20 0.71
▸ FLT3 P36888 3/20 0.71
▸ ALK Q9UM73 2/20 0.71
▸ FLT1 P17948 2/20 0.71
▸ PDGFRA P16234 1/20 0.71
▸ NTRK1 P04629 7/20 0.70
▸ JAK3 P52333 3/20 0.68
▸ SYK P43405 1/20 0.68
▸ ATM Q13315 1/20 0.68
▸ CHEK1 O14757 1/20 0.68
▸ AURKA O14965 1/20 0.68
▸ DAPK3 O43293 1/20 0.68
▸ PRKD3 O94806 1/20 0.68
▸ MAP4K4 O95819 1/20 0.68
▸ LCK P06239 1/20 0.68
▸ FYN P06241 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728251 0.89 PDGFRB (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL5728248 0.89 PDGFRB (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL18054 0.83 PDPK1 (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL18053 0.83 PDPK1 (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL5373346 0.83 PDPK1 (0.71) PDGFRBTLK2PDPK1RETKDR
SCHEMBL19691 0.83 PDPK1 (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL3912682 0.83 PDGFRB (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL19692 0.83 PDPK1 (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL5727973 0.83 PDPK1 (1.00) PDGFRBTLK2PDPK1RETKDR
SCHEMBL5728408 0.83 PDPK1 (0.76) PDGFRBTLK2PDPK1RETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111116452-B Indolone derivatives with alpha-glucosidase inhibitory activity as well as preparation method and application thereof 五邑大学 2022-05-03 — — CN disclosed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, HTT, PARK7 PDGFRB 2159/4885TLK2 2365/4885PDPK1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback